Swiss biotech Molecular Partners, backed by several venture capital firms, is set to raise CHF 96m in its IPO on the Swiss Exchange, having resumed flotation plans after delaying the listing last month.
Deal will be the second add-on acquisition for Danoffice since Agilitas's buyout of the company in November 2017
Bowmark will provide additional funding of £100m to fund the company's add-ons acquisitions
Exit represents an 18x return on Octopus's initial investment and a 9x return on its total investment
Deal follows M&A litigation initiated after coronavirus uncertainty and financing difficulties